SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biopicker who wrote (2279)10/10/1997 8:19:00 PM
From: JOHN W.   of 6136
 
L. Moss on AOL has proven that he has had a very accurate model for sales: Another interesting post:

Subject: Comparing apples to apples
Date: Wed, Oct 8, 1997 08:33 EDT
From: LMoss
Message-id: <19971008123301.IAA12909@ladder02.news.aol.com>

Of the $79.5 million in reported 1QF98 Viracept sales, $4.1 million were sales to Roche for use in Europe. U.S. sales were thus $75.4 million, which is the number to compare with my estimate of $70 million. (All of my previous estimates of Viracept sales were for the U.S. alone.)

Incidentally, I understand that Roche is now selling Viracept in France and Germany (as well as Switzerland) under a "special license" program.

I'll soon post estimates of European sales of Viracept. When these are added to my estimate of U.S. sales in F98 of $550 million, and revenues from contract and license fees and royalties are also added, I estimate that total Agouron revenues in F98 will be well above $700 million.

LMoss

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News